IDEXX Lifts 2026 Revenue And EPS Outlook After 10% Sales Growth, But Cuts Margin Guidance

Third-quarter revenue reached $1,214 million and EPS $4.01, while the full-year operating margin outlook slipped to 32.1%–32.3%.

Share
IDEXX Lifts 2026 Revenue And EPS Outlook After 10% Sales Growth, But Cuts Margin Guidance

IDEXX Laboratories, which makes diagnostics and software for veterinary clinics, raised its 2026 revenue and earnings guidance on Monday after third-quarter revenue grew 10% to $1,214 million. It also lowered its full-year operating margin outlook, to 32.1%–32.3% from 32.3%–32.5%, and said the updated guidance includes acquisition-related impacts.

Quarter driven by recurring testing

Diluted earnings per share were $4.01, up 18% as reported and 22% on a comparable basis, the company said in an 8-K. The quarter included a $0.03 per share benefit from a non-operating gain on an equity investment, $0.01 from share-based compensation tax benefits and $0.04 from currency changes.

Recurring diagnostics revenue at the Companion Animal Group, the veterinary-clinic business that is IDEXX's largest, grew 11% as reported and organically. International regions grew 13% as reported and 14% organically, and the U.S. grew 10%.

VetLab consumables revenue grew 14% as reported and 15% organically. Reference laboratory services grew 10%, while rapid assay products rose 1%. Instrument capital revenue was flat, even as IDEXX placed more than 1,900 inVue Dx analyzers, taking its installed base to nearly 11,000.

Water revenue rose 8% and livestock, poultry and dairy revenue 3%. Operating margin was 33.1%, up 100 basis points (a full percentage point) as reported and 60 basis points on a comparable basis. Free cash flow was $420.8 million, against $371.2 million a year earlier.

Guidance up, margin down

IDEXX now expects 2026 revenue of $4,741 million–$4,767 million, up $32 million at the midpoint from $4,700 million–$4,745 million. That includes $5 million from the recent CoVet acquisition. Organic growth is projected at 9.3%–10.0%.

The EPS outlook rose to $14.96–$15.16 from $14.69–$14.94, a $0.25 increase at the midpoint. The lower margin range implies full-year expansion of 50 to 70 basis points, down from 70 to 90.

CEO Mike Erickson said the company "delivered exceptional third quarter results," pointing to inVue Dx with FNA, a multi-cancer version of IDEXX Cancer Dx, and the CoVet acquisition, an AI clinical assistant for veterinary teams.

Calls and an analyst session

IDEXX hosts a conference call at 8:30 a.m. ET Monday to discuss the results. It will also hold an investor and analyst session on its MultiCue Dx analyzer at VMX in Orlando on Monday, January 18, at 1:00 p.m. ET.

The next checkpoint is the January 18 session in Orlando, where IDEXX will showcase MultiCue Dx, its next point-of-care analyzer.

Sources

More on IDEXX Laboratories

All IDEXX Laboratories (IDXX) coverage →